Press Release

Ebitda Margin ExpansionExceptional ItemPat Growth 25pctResults View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.6%Reaction day

₹992.00

prior close

₹1036.40

announcement price

In-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.0%+2.6% vs market

Pharmaceuticals peers, median of 159sector+0.7%+1.9% vs sector

On the reaction day the stock moved 2.6 pts more than Nifty 100 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.1

15m

+0.8

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.6-0.0+2.6+0.7+1.9

Next day

+4.9+0.2+4.6+1.2+3.7

+4.5+0.3+4.3+1.4+3.2

+4.7+0.6+4.1+0.8+3.9

+8.0+1.9+6.1+1.9+6.0

+8.6+1.5+7.0+2.2+6.3

+9.1+0.3+8.8+2.1+7.0

15d

+10.6-1.4+11.9+1.6+9.0

+8.1+2.3+5.8+3.3+4.8

+15.8+3.1+12.7+8.7+7.1

+11.3+2.9+8.5+9.5+1.8

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences reported strong Q4 FY26 results with revenue up 16% YoY to Rs. 75,870 mn and EBITDA up 20% YoY to Rs. 25,544 mn. EBITDA margin expanded by 110 bps to 33.7%. Net profit grew 15% YoY to Rs. 15,929 mn. For the full year, revenue reached Rs. 271,484 mn (up 17%), EBITDA was Rs. 84,751 mn (up 20%), and net profit was Rs. 54,564 mn (up 15%). The Board recommended 100% dividend and approved a share buyback of up to Rs. 11,000 mn at Rs. 1,150 per share. Exceptional items included Rs. 3,975 mn for Mirabegron litigation settlement. India Formulations grew 14% YoY while Consumer Wellness surged 61% YoY; North America declined 6% YoY.

Likely market impact

Strong operational performance with margin expansion and shareholder returns through dividend and buyback signal financial health. The buyback at 16% premium to market price could provide near-term support to the stock price.